Great Lakes Advisors LLC Sells 14,747 Shares of Halozyme Therapeutics, Inc. $HALO

Great Lakes Advisors LLC lowered its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 10.9% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 120,980 shares of the biopharmaceutical company’s stock after selling 14,747 shares during the period. Great Lakes Advisors LLC’s holdings in Halozyme Therapeutics were worth $8,873,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Campbell Newman Asset Management Inc. lifted its position in Halozyme Therapeutics by 0.4% in the third quarter. Campbell Newman Asset Management Inc. now owns 36,878 shares of the biopharmaceutical company’s stock valued at $2,705,000 after purchasing an additional 153 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Halozyme Therapeutics by 6.9% in the second quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock valued at $140,000 after acquiring an additional 174 shares during the period. Richardson Financial Services Inc. grew its stake in shares of Halozyme Therapeutics by 87.6% in the third quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 198 shares during the last quarter. Brown Advisory Inc. grew its position in shares of Halozyme Therapeutics by 0.6% in the 2nd quarter. Brown Advisory Inc. now owns 35,057 shares of the biopharmaceutical company’s stock worth $1,824,000 after buying an additional 224 shares during the last quarter. Finally, Global Retirement Partners LLC boosted its holdings in Halozyme Therapeutics by 21.6% in the third quarter. Global Retirement Partners LLC now owns 1,413 shares of the biopharmaceutical company’s stock valued at $104,000 after acquiring an additional 251 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have weighed in on HALO shares. The Goldman Sachs Group reaffirmed a “sell” rating and set a $56.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, December 4th. Wall Street Zen lowered Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday, December 6th. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a report on Tuesday, November 4th. Leerink Partners raised shares of Halozyme Therapeutics from an “underperform” rating to a “market perform” rating and set a $70.00 price objective for the company in a report on Tuesday, October 14th. Finally, Morgan Stanley cut their price objective on Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating for the company in a report on Monday, October 20th. Seven research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $78.80.

Insider Transactions at Halozyme Therapeutics

In related news, Director Bernadette Connaughton sold 2,000 shares of the business’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $70.25, for a total value of $140,500.00. Following the sale, the director directly owned 40,123 shares in the company, valued at approximately $2,818,640.75. The trade was a 4.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Helen Torley sold 16,569 shares of the company’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $68.92, for a total value of $1,141,935.48. Following the sale, the chief executive officer directly owned 708,719 shares in the company, valued at $48,844,913.48. This trade represents a 2.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 45,661 shares of company stock valued at $3,139,257. 2.40% of the stock is currently owned by insiders.

Halozyme Therapeutics News Summary

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Company raised guidance and posted strong preliminary 2025 metrics — Halozyme updated preliminary 2025 revenue to $1.385–$1.40B and raised 2026 revenue guidance to $1.71–$1.81B; it also lifted royalty, adjusted EBITDA and non?GAAP EPS guidance, signaling stronger top?line and cash?flow outlooks. PR Newswire
• Positive Sentiment: Market reacted to the stronger preliminary results and raised outlook — coverage notes a near?term share uptick after management lifted 2026 guidance and preliminary 2025 results beat expectations. This supports momentum and re?rates HALO on growth expectations. Zacks
• Positive Sentiment: Acquisition of Surf Bio expands drug?delivery capabilities — Halozyme bought Surf Bio (deal up to $400M) to add a hyperconcentration technology that complements its ENHANZE platform, potentially expanding addressable markets for biologics delivery and future royalty streams. Contract Pharma
• Positive Sentiment: Analyst support — H.C. Wainwright reiterated a Buy and keeps a $90 price target, citing strategic and financial strength of the ENHANZE platform, which may sustain analyst/retail demand. InsiderMonkey
• Neutral Sentiment: Longer?term projections published — Management outlined sustained growth into the 2030s/2040s driven by ENHANZE and new technologies; important for long?term investors but less decisive for near?term moves. Benzinga
• Neutral Sentiment: Management call and filings available — Q4/2025 sales/trading call transcript and slides provide detail for modeling royalty cadence, margin assumptions and Surf Bio integration plans; useful for updating forecasts. Seeking Alpha
• Negative Sentiment: EPS guidance nuance — 2026 non?GAAP EPS was set at $7.75–$8.25 versus consensus ~ $7.86; while revenue/royalty guidance was raised, the EPS range overlaps but is not meaningfully above consensus, which could temper upside for EPS?sensitive investors. PR Newswire

Halozyme Therapeutics Trading Up 0.7%

Shares of Halozyme Therapeutics stock opened at $73.34 on Friday. The company has a debt-to-equity ratio of 1.59, a quick ratio of 1.37 and a current ratio of 1.59. Halozyme Therapeutics, Inc. has a fifty-two week low of $47.50 and a fifty-two week high of $79.50. The company has a fifty day moving average of $68.90 and a 200 day moving average of $68.27. The company has a market capitalization of $8.62 billion, a P/E ratio of 15.44, a P/E/G ratio of 0.32 and a beta of 0.94.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 EPS for the quarter, topping analysts’ consensus estimates of $1.63 by $0.09. The company had revenue of $354.26 million for the quarter, compared to analysts’ expectations of $339.18 million. Halozyme Therapeutics had a return on equity of 156.95% and a net margin of 47.91%.The firm’s revenue was up 22.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.27 EPS. On average, sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.